Assay ID | Title | Year | Journal | Article |
AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1508629 | Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1508628 | Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1508627 | Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3
| High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID1449931 | Inhibition of RND efflux pump in Pseudomonas aeruginosa PAO1 assessed as potentiation of minocycline-induced antibacterial activity at 8 ug/ml after 18 to 24 hrs by checker board assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
| A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
AID1449983 | Inhibition of RND efflux pump in Enterobacter cloacae isolate 117029 assessed as potentiation of minocycline-induced antibacterial activity by measuring minocycline MIC at 8 ug/ml after 18 to 24 hrs by microbroth dilution assay (Rvb = 128 to 256 ug/ml) | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
| A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
AID1449984 | Inhibition of RND efflux pump in Klebsiella pneumoniae isolate 116381 assessed as potentiation of minocycline-induced antibacterial activity at 8 ug/ml after 18 to 24 hrs by microbroth dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
| A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
AID1471318 | Potentiation of florfenicol induced-antimicrobial activity against multi drug-resistant Escherichia coli AG112 assessed as fold reduction in florfenicol MIC at 100 ug/ml by broth microdilution method | 2017 | Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
| Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms. |
AID1449968 | Inhibition of RND efflux pump in XDR Pseudomonas aeruginosa isolate P262-101856 infected in Galleria mellonella assessed as potentiation of minocycline-induced antibacterial activity by measuring larval death rate at 75 mg/kg co-treated with 75 mg/kg mino | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
| A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
AID575167 | Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in marR mutant containing Escherichia coli K-12 3-AG102 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
| Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates. |
AID575170 | Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
| Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates. |
AID1471320 | Potentiation of tetracycline induced-antimicrobial activity against multi drug-resistant Escherichia coli AG112 assessed as fold reduction in tetracycline MIC at 100 ug/ml by broth microdilution method | 2017 | Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
| Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms. |
AID1449985 | Inhibition of RND efflux pump in Enterobacter cloacae isolate 117029 assessed as potentiation of minocycline-induced antibacterial activity at 8 ug/ml after 18 to 24 hrs by microbroth dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
| A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
AID575161 | Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 800 uM by spectrofluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
| Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates. |
AID1449982 | Inhibition of RND efflux pump in Klebsiella pneumoniae isolate 116381 assessed as potentiation of minocycline-induced antibacterial activity by measuring minocycline MIC at 8 ug/ml after 18 to 24 hrs by microbroth dilution assay (Rvb = 128 ug/ml) | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
| A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
AID575166 | Inhibition of acrAB AcrAB-TolC in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as [3H]TMG accumulation at 800 uM by scintillation counter method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
| Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates. |
AID1449967 | Inhibition of RND efflux pump in XDR Pseudomonas aeruginosa isolate P262-101856 infected in Galleria mellonella assessed as potentiation of minocycline-induced antibacterial activity by measuring larval survival rate at 75 mg/kg co-treated with 75 mg/kg m | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
| A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
AID1471319 | Potentiation of ciprofloxacin induced-antimicrobial activity against multi drug-resistant Escherichia coli AG112 assessed as fold reduction in ciprofloxacin MIC at 100 ug/ml by broth microdilution method | 2017 | Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
| Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms. |
AID1449986 | Antibacterial activity against Klebsiella pneumoniae isolate 116381 after 18 to 24 hrs by microbroth dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
| A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
AID1449987 | Antibacterial activity against Enterobacter cloacae isolate 117029 after 18 to 24 hrs by microbroth dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
| A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
AID1449929 | Inhibition of RND efflux pump in Pseudomonas aeruginosa PAO1 assessed as potentiation of minocycline-induced antibacterial activity by measuring minocycline MIC at 8 ug/ml after 18 to 24 hrs by microbroth dilution assay (Rvb = 8 ug/ml) | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
| A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
AID575169 | Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
| Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates. |
AID575168 | Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in marR mutant containing Escherichia coli K-12 3-AG102 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric a | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
| Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates. |
AID1449930 | Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 to 24 hrs by microbroth dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
| A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
AID1450005 | Inhibition of RND efflux pump in Pseudomonas aeruginosa PAO1 assessed as increase in tetracycline uptake up to 5.7 ug/ml measured at 1 min interval for 30 mins by fluorescence assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
| A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
AID1449965 | Antibacterial activity against XDR Pseudomonas aeruginosa isolate P262-101856 infected in Galleria mellonella assessed as protection against bacterial infection by measuring larval death at 75 mg/kg up to 24 hrs relative to control | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
| A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
AID575163 | Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose by spectrofluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
| Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |